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OBJECTIVE: To identify differences in management levels and
costs between nursing home (NH) residents with and without
Clostridium difﬁcile associated diarrhea (CDAD). METHODS:
Minnesota long-term care data from 1995–2001 were examined
for residents with (ICD-9-CM code: 008.45) and without
CDAD. NH residents are assigned to one of eleven management
categories reﬂecting low to very high care needs, based on assess-
ment of dependence in activities of daily living (ADL), need for
skilled nursing and behavior. Reimbursement rates are set for
each management category based on expected care needs.
Dependence in ADL, need for skilled nursing, behavior and
assigned management category were analyzed. Costs were esti-
mated by applying Minnesota NH reimbursement rates, adjusted
to national values to each management proﬁle. Cost estimates
(2002 US$) include room and board, nursing and ancillary staff
care. RESULTS: CDAD was coded for 260 (0.1%) of the
220,123 NH residents analyzed. Age and gender were similar for
both groups. Residents with CDAD had signiﬁcantly more bowel
incontinence (p = 0.000), required more skilled nursing services
(p = 0.000) and were more dependent in walking (p = 0.001),
transferring (p = 0.002), bed mobility (p = 0.003), as well as in,
albeit not statistically signiﬁcant (p > 0.5), dressing, bathing and
eating. Residents without CDAD had signiﬁcantly more (p =
0.001) behavioral problems and were slightly more dependent (p
> 0.05) in grooming. Increased ADL dependency and need for
skilled nursing resulted in residents with CDAD being assigned
to higher management categories signiﬁcantly (p = 0.000) more
often than those without CDAD. This increase in management
results in an additional $2985 in care costs annually per NH res-
ident with CDAD, on average. CONCLUSIONS: CDAD consti-
tutes a physical burden to the resident and an economic burden
to the long term care system in terms of direct care costs, as well
as opportunity costs due to the need for increased skilled nursing
services.
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OBJECTIVES: The National Institute for Clinical Excellence
(NICE) recently published guidance on the use of peginterferon
alfa-2a (40KD) and peginterferon alfa-2b (12KD) for the 
treatment of adults with CHC (http://www.nice.org.uk/pdf/
TA075guidance.pdf). However, from a cost-effectiveness per-
spective, this guidance does not differentiate between either the
efﬁcacy or the costs of the two treatments. Therefore, in the
absence of any direct head-to-head trials, a reliable indirect com-
parison may create a more informed, evidence-based choice for
payers and clinicians. METHODS: The Bucher method (J.Clin
Epidemiol 1997;50:683–91) is a mathematical technique that
indirectly compares drugs without bias. Indeed, evidence sug-
gests (Song, et al. BMJ 2003;326:472) that results calculated
with this method are not signiﬁcantly different from those
obtained using direct comparisons. We therefore used this
method to evaluate the relative treatment effects of the two
peginterferons in combination with ribavirin, compared to a
common comparator (conventional interferon alfa plus rib-
avirin). This allowed the relative effectiveness of the two drugs
to be compared. These results, expressed as adjusted sustained
virological response (SVR) rates, were then entered into a previ-
ously published Markov model to assess the incremental cost-
effectiveness. RESULTS: Following adjustment for SVR rate in
the common control arms (by Bucher method), peginterferon
alfa-2a (40KD) plus ribavirin resulted in a higher number of
expected discounted quality-adjusted-life-years (QALYs) in both
HCV genotype 1 (14.12 vs. 14.08) and non-1 (14.95 vs. 14.68)
patients compared with peginterferon alfa-2b (12KD) plus rib-
avirin. Peginterferon alfa-2a (40KD) plus ribavirin also gener-
ates lower direct NHS (National Health Service) costs for
genotype 1 (£24,064 vs. £24,488) and non-1 patients (£11,446
vs. £15,332) than peginterferon alfa-2b (12KD) plus ribavirin.
CONCLUSION: Compared to peginterferon alfa-2b (12KD)
plus ribavirin, peginterferon alfa-2a (40KD) plus ribavirin is
likely to be the dominant treatment strategy for patients with
CHC in the UK, generating better outcomes (QALYs), with
lower direct NHS costs.
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OBJECTIVES: Acute otitis media (AOM) is an important
problem mainly in children age. It often results in serious ill-
nesses such as pneumonia, meningitis and accumulated ﬂuid can
cause signiﬁcant hearing impairment, and may interfere with the
development of normal speech in infancy. Antimicrobials are
treatment of choice. Our objective was to analyze antibiotic pre-
scribing and evaluate cost of antimicrobial treatment acute otitis
media. METHODS: Same protocols and methodology was
applied for multicentric study; 4 weeks prospective study in
November 2003; 66 paediatricians in 5 Slovak cities. Validation
of antibiotic prescribing according guidelines. CMA (cost-min-
imisation analysis) was used. Utilisation of antibiotics in WHO
ATC/DDD system. RESULTS: Out of 326 patients, to 179
(54.9%) were indicated antibiotic treatment. The most frequent
prescribing antibiotic were co-aminopenicillins (J01CR) in 54
patients (31.2%, 229.5 DDD), second were penicillins (J01CE)
in 37 cases (21.4%, 143 DDD), then cephalosporins (J01D) in
35 cases (20.2%, 129 DDD), aminopenicillins (J01CA) in 24
cases (13.9%, 135.4 DDD), macrolides (J01FA) in 18 cases
(10.4%, 109 DDD). The largest rate of total cost for antimicro-
bial therapy of AOM was spending for alternative choices: 
co-aminopenicillins (36.5), cephalosporines (24.3%) and
macrolides (24.1%). Cost for amoxicillin as ﬁrst choice drug was
4.3%, for alternative antimicrobials 84.9% and other antimi-
crobials (10.8%). CONCLUSIONS: Acute otitis media is serious
infection illness which needs to be cured by antimicrobials. More
often were indicated alternative antibiotics, with more expensive
average cost for therapy. Reasonable use of antibiotic is neces-
sary to maintain the resistance at low level and aim to decrease
total cost.
